Clinical Trial

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bortezomib, lenalidomide, and dexamethasone are more or less effective than carfilzomib, lenalidomide, and dexamethasone in treating patients with multiple myeloma
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2013-05-23; most recent amendment 2025-09-04.
Status change: Recruiting → Active, Not Recruiting 2019-11-07
Status change: Not Yet Recruiting → Recruiting 2014-02-04
Trial Details
NCT Number NCT01863550
Lead Sponsor ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Conditions Plasma Cell Myeloma
Enrollment 1,087 participants
Start Date 2013-12-06
Primary Completion 2026-12-31 (estimated)
Study Completion 2034-02-05 (estimated)
Updated on ClinicalTrials.gov 2025-09-08